Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Published:2019-07 Issue:7 Volume:20 Page:984-997
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cortes Jorge E,Khaled Samer,Martinelli Giovanni,Perl Alexander E,Ganguly Siddhartha,Russell Nigel,Krämer Alwin,Dombret Hervé,Hogge Donna,Jonas Brian A,Leung Anskar Yu-Hung,Mehta Priyanka,Montesinos Pau,Radsak Markus,Sica Simona,Arunachalam Meena,Holmes Melissa,Kobayashi Ken,Namuyinga Ruth,Ge Nanxiang,Yver Antoine,Zhang Yufen,Levis Mark J

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?;Levis;Hematology Am Soc Hematol Educ Program,2013

2. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy;Boissel;Leukemia,2002

3. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study;Ravandi;Lancet Oncol,2015

4. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study;Chevallier;Leukemia,2011

5. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure;Wattad;Leukemia,2017

Cited by 330 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants;Bioorganic Chemistry;2024-02

2. Design and Synthesis 1H-Pyrrolo[2,3-b]pyridine Derivatives as FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia;Bioorganic & Medicinal Chemistry;2024-02

3. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China;Clinical Pharmacology in Drug Development;2024-01-29

4. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?;Journal of Clinical Medicine;2024-01-18

5. High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies;Microorganisms;2024-01-06